Dr Davendra P Ramkumar, MD | |
3101 Fields South Dr, Champaign, IL 61822-3743 | |
(217) 366-6212 | |
Not Available |
Full Name | Dr Davendra P Ramkumar |
---|---|
Gender | Male |
Speciality | Gastroenterology |
Experience | 31 Years |
Location | 3101 Fields South Dr, Champaign, Illinois |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063420370 | NPI | - | NPPES |
036905912 2 | Medicaid | IL | |
279500 | Other | MEDICARE GROUP | |
P00178098 | Other | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RG0100X | Internal Medicine - Gastroenterology | 036-112654 (Illinois) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
The Carle Foundation Hospital | Urbana, IL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Christie Clinic, Llc | 7719899319 | 200 |
News Archive
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomerâ„¢ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences ("NT Life"), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Vorys' fifth and newest blog was launched to provide interesting and pertinent analysis of a variety of issues involving health information technology (HIT). The blog, available at www.healtHITechlaw.com, will provide readers with frequent updates on developments in HIT, including HIPAA/HITECH compliance and the interplay of state privacy laws, electronic health record implementation and use challenges, review of new HIT tools and status of health information exchanges.
Enzon Pharmaceuticals, Inc. announced today that its Board of Directors has authorized the repurchase of up to $50 million of its outstanding shares of common stock in order to return value to its shareholders.
› Verified 1 days ago
Entity Name | Christie Clinic, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1871523829 PECOS PAC ID: 7719899319 Enrollment ID: O20031103000332 |
News Archive
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomerâ„¢ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences ("NT Life"), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Vorys' fifth and newest blog was launched to provide interesting and pertinent analysis of a variety of issues involving health information technology (HIT). The blog, available at www.healtHITechlaw.com, will provide readers with frequent updates on developments in HIT, including HIPAA/HITECH compliance and the interplay of state privacy laws, electronic health record implementation and use challenges, review of new HIT tools and status of health information exchanges.
Enzon Pharmaceuticals, Inc. announced today that its Board of Directors has authorized the repurchase of up to $50 million of its outstanding shares of common stock in order to return value to its shareholders.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Davendra P Ramkumar, MD 101 W University Ave, Champaign, IL 61820-3909 Ph: (217) 366-6212 | Dr Davendra P Ramkumar, MD 3101 Fields South Dr, Champaign, IL 61822-3743 Ph: (217) 366-6212 |
News Archive
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomerâ„¢ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences ("NT Life"), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.
Diabetes is a global health concern expected to affect 693 million people worldwide by 2045. It's been well documented how diet and exercise influence risk of type 2 diabetes; however, a new study suggests that early menarche also is associated with a higher risk, but body mass index may mediate this association.
Vorys' fifth and newest blog was launched to provide interesting and pertinent analysis of a variety of issues involving health information technology (HIT). The blog, available at www.healtHITechlaw.com, will provide readers with frequent updates on developments in HIT, including HIPAA/HITECH compliance and the interplay of state privacy laws, electronic health record implementation and use challenges, review of new HIT tools and status of health information exchanges.
Enzon Pharmaceuticals, Inc. announced today that its Board of Directors has authorized the repurchase of up to $50 million of its outstanding shares of common stock in order to return value to its shareholders.
› Verified 1 days ago
Sarah Lovinger, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1701 Curtis Rd, Champaign, IL 61822 Phone: 217-365-6207 Fax: 217-365-6380 | |
Esha Patel, MD,MHA Gastroenterology Medicare: Medicare Enrolled Practice Location: 1050 Baytowne Dr Apt 24, Champaign, IL 61822 Phone: -- | |
Mr. Jason Trager, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 101 W University Ave, Champaign, IL 61820 Phone: 217-366-1304 | |
Dr. Yasser Ali Haider, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1801 W Windsor Rd, Champaign, IL 61822 Phone: 217-366-1372 | |
Dr. Andrew J. Bartlett, D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1801 W Windsor Rd, Champaign, IL 61822 Phone: 217-366-5434 Fax: 217-366-8074 | |
Amanda Walker, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1701 Curtis Rd, Adult Medicine, Champaign, IL 61822 Phone: 217-365-6207 Fax: 217-365-6380 |